drugset
drugset / Trial / NCT01260714

Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia

NCT01260714 ↗

Phase 1 Terminated 13 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the best dose of azacitidine and to see how well it works with mitoxantrone hydrochloride and etoposide in treating older patients with acute myeloid leukemia that has a lower chance of responding to treatment or higher risk of returning (poor prognosis). Drugs used in chemotherapy, such as azacitidine, mitoxantrone hydrochloride, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

Timeline

Start
2010-12
Primary completion
2015-03
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Subcutaneous
Subject Etoposide Small molecule — Intravenous
Subject Mitoxantrone Small molecule — Intravenous

Indications

acute basophilic leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(9;11)(p22;q23) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myeloid leukemia, t(8;21)(q22; q22.1) acute myelomonocytic leukemia M4 adult acute monocytic leukemia erythroleukemia